Due to its high brain permeability, this drug was initially tested against Alzheimer’s disease (where Hsp90 is a relevant target) with the completion of Phase 1 (NCT03935568) allowing it to move to Phase 2 clinical trials (NCT04311515) [47,48]. Here, HSP90AB1 is linked to early-onset autosomal dominant Alzheimer disease.